Nasdaq · Healthcare
Tarsus Pharmaceuticals, Inc. (TARS)
As-reported financials and recent SEC filings for Tarsus Pharmaceuticals, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$451.4M
Net income
$-66.4M
Net margin
-14.7%
Diluted EPS
$-1.59
ROE
-19.3%
P/E (TTM)
—
Market cap
$2.71B
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $451.4M | $183.0M | $17.4M | $25.8M | $57.0M |
| Gross profit | — | — | — | — | — |
| Operating income | $-71.0M | $-120.6M | $-143.2M | $-62.7M | $-12.2M |
| Net income | $-66.4M | $-115.6M | $-135.9M | $-62.1M | $-13.8M |
| Diluted EPS | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →42026-06-17
View on EDGAR →1442026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-16
View on EDGAR →1442026-06-16
View on EDGAR →42026-06-16
View on EDGAR →Go deeper on TARS
Search Tarsus Pharmaceuticals, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.